Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.

Genentech Notifies 340B Entities of Limited Distribution of Key COVID-19 Drug

In Pharma IndustrySeptember 2, 2021241 Views

Ron Shinkman

Biopharmaceutical manufacturer Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Ron Shinkman

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden

*Sign up for news summaries and alerts from 340B Report